Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px
Document › Details

Ipsogen S.A.. (4/4/11). "Press Release: Ipsogen and Sysmex Establish a Distribution Agreement for the Japanese Market". Marseille.

Region Region Japan
Organisations Organisation Ipsogen S.A.
  Today Qiagen Marseille S.A.
  Group Qiagen (Group)
  Organisation 2 Sysmex Corporation
  Today Sysmex (Group)
  Group Sysmex (Group)
Products Product cancer test
  Product 2 molecular diagnostics
Person Person Fert, Vincent (HalioDx 201503– CEO + CO-founder before Ipsogen 200708– President + CEO)
     


IPSOGEN (Alternext - FR0010626028 - ALIPS), Cancer Profiler, who develops, manufactures and commercializes molecular diagnostic assays for leukemia and breast cancer, announces today an agreement under which SYSMEX will distribute certain IPSOGEN blood cancer products in Japan. The agreement covers regulatory submission of IPSOGEN products applicable to the diagnostic and monitoring of BCR-ABL and JAK2 (or Myeloproliferative Neoplasms) to Japanese Health Authorities and gives SYSMEX exclusive rights to sell these products in Japan. Financial details were not disclosed.

"Together with the rest of the international community, we share the sorrow and anguish of the Japanese people after the terrible earthquake and tsunami which have deeply hurt their country. We have gone through business discussions and important meetings in regards to this partnership since last year and feel today satisfied to have reached this agreement. We are indeed very pleased to partner with SYSMEX, with its global leadership position within hematology and its knowledge of its home market, to expand our commercial efforts to Japan and carry on our market penetration" said Vincent Fert, Chief Executive Officer of IPSOGEN. "We believe the combination of SYSMEX marketing reach and expertise in hematology and the unique IPSOGEN products offering represent an excellent opportunity for Japanese patients to access to our standardized solutions for the personalized treatment of blood cancer".


About IPSOGEN

IPSOGEN, Cancer Profiler, develops and markets molecular diagnostic tests that help map diseases in order to guide patients and oncologists' decisions along their therapeutic path. With more than 80 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, IPSOGEN is now targeting breast cancer with the aim of providing as yet inaccessible diagnostic information. Strengthened by its scientific, clinical and technological partnerships, and by its multidisciplinary team in France and the USA, IPSOGEN targets to become a world leader in the molecular profiling of cancers, and to pursue the development and promotion of diagnostic standards that have a significant impact on patients, medical professionals and society. The company, which headquarters are in Marseille, France has a subsidiary in the USA. For further information, please visit www.ipsogen.com.


About SYSMEX

SYSMEX Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 42 years, SYSMEX focuses on technological leadership in diagnostic science and information tools that make a real difference in the health of people worldwide. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, China and Asia Pacific and employs more than 4,600 employees worldwide. SYSMEX Corporation is listed in the top tier of the Tokyo Stock Exchange. For more information about SYSMEX Corporation and its affiliate companies, please visit www.sysmex.com.

Contacts

IPSOGEN

Vincent Fert
CEO
Tel: + 33 (0)4 9129 3090
fert@ipsogen.com

Pascale Boissel
CFO
Tel: + 33 (0)4 9129 3090
pascale.boissel@ipsogen.com

ATCG Press
Corporate and Product
Information
Marielle Bricman
Tel: + 33 (0)4 9125 0785
ipsogen@atcg-partners.com

NewCap.
Financial communication
& Investor relations
Axelle Vuillermet &
Pierre Laurent
Tel: + 33 (0)1 44 71 94 93
ipsogen@newcap.fr

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Qiagen (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top